Representative Transactions*

• Takeda Pharmaceutical Company in collaboration and supply agreements with Moderna and the Ministry of Health, Labour & Welfare of Japan for the clinical development, regulatory approval, supply and distribution of Moderna’s mRNA-1273 COVID-19 vaccine in Japan
• International AIDS Vaccine Initiative (IAVI) in collaboration with Merck KGaA and Serum Institute of India to develop SARS-CoV-2 neutralizing monoclonal antibodies (developed by IAVI and Scripps Research)

• Xencor in a strategic collaboration and license agreement with Atreca to research, develop and commercialize T cell engaging bispecific antibody therapeutics in oncology
• Takeda Pharmaceutical Company in its license and collaboration arrangement with Novavax for production and commercialization of Novavax’s COVID-19 vaccine candidate
• Engage Therapeutics, developer of Staccato® Alprazolam for rapid termination of an active epileptic seizure, by UCB Pharma for $125M with up to $145M in milestone payments.
• Hansoh Pharmaceutical Group in a strategic collaboration, exclusive license and supply agreement with EQRx for the development and commercialization by EQRx of Hansoh’s almonertinib in the United States, Europe and Japan
• OliX Pharmaceuticals in an exclusive license and supply agreement with AM Chemicals for GalNAc conjugate technology and materials for OliX’s asymmetric small interfering RNA (asiRNA) for liver targeting
• Antares Pharma in its agreement with Idorsia Pharmaceuticals for the development of a novel drug device combination product to be developed for the treatment of suspected acute myocardial infarction
• Dewpoint Therapeutics in its option, research and license agreement with Bayer valued up to $100M that will leverage Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule compound library to develop new treatments for cardiovascular and gynecological diseases
• Celgene Corporation in its amended collaboration agreement with Editas Medicine, which allows the parties to research, develop and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases, and enables Editas Medicine to receive an upfront payment of $70M as well as potential future milestones and royalty payments
• Gilead Sciences in its research and development collaboration valued up to $475M with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology and to access Carna's proprietary lipid kinase drug discovery platform
• Antares Pharma in its agreement with Pfizer to develop a combination drug device overdose rescue pen under which Pfizer will develop and commercialize the product in the U.S. and Antares will receive royalties on net sales
• Talee Bio, a gene therapy company developing the next generation treatment and cures for cystic fibrosis, in its sale to Roivant Sciences
• Merck in an exclusive worldwide license and collaboration agreement with Cocrystal Pharma research, development and commercialization of antiviral therapeutics including for influenza, hepatitis C and noroviruses
• Xencor in a collaboration agreement with Astellas to generate bispecific antibodies directed toward a selected tumor target using Xencor’s modular antibody engineering platform for the treatment of cancer
• Humabs BioMed, a spinoff from the Institute of Biomedical Research Bellinzona, Switzerland, developing monoclonal antibody therapeutics, in its acquisition by Vir Biotechnology
• Natera in its agreement with Qiagen to develop cell-free DNA assays for use on Qiagen’s GeneReader NGS System for prenatal screening
• AxeroVision in its spinout from GSK with certain ophthalmic assets, with investment and license arrangement with Laboratoires Thea
• Ash Stevens, a Michigan-based contract process development and manufacturing organization, in its acquisition by India-based Piramal Enterprises
• CrystalGenomics in a license, development and commercialization agreement on cancer therapeutic lead with Aptose
• Gilead Sciences in a license and collaboration agreement with MicroDose Therapeutx to develop and commercialize MicroDose’s inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus infections
• Novadaq Technologies in a multiyear license and development agreement with Intuitive Surgical to integrate Novadaq’s SPY fluorescence imaging technology into the 3D, high-definition imaging capabilities of Intuitive’s da Vinci® Surgical Robot Systems
• Topcon Medical Laser Systems, Inc. in its acquisition of therapeutic laser technologies and retina and glaucoma business of OptiMedica Corporation
• Ash Stevens, Inc. in commercial supply agreement with Pharmion (subsequently acquired by Celgene) for API for Vidaza®
• Novadaq Corp. in its acquisition of exclusive United States distribution rights for PLC Medical System’s HEART LASERTM SYSTEM for transmyocardial revascularization (TMR) from Edwards Lifesciences
• Chiron Corporation (now part of Novartis) in a license agreement with Cubist Pharmaceuticals to develop and commercialize Cubicin® (Daptomycin for injection), an antibiotic approved for treatment of complicated skin and skin structure infections caused by gram-positive bacteria
• InSite Vision Incorporated in a collaboration with Bausch & Lomb for the development and commercialization of a fourth-generation fluoroquinolone combined with InSite Vision’s proprietary ophthalmic drug delivery technology
• Konica Minolta in a comprehensive business partnership and capital investment agreement with Konarka Technologies for the development and distribution of organic thin-film photovoltaics
• Nuvelo (formerly Hyseq Pharmaceuticals, Inc.) in a collaboration with Amgen to develop and commercialize Alfimeprase, a novel acting thrombolytic, for the treatment of catheter occlusion and peripheral arterial occlusion
• MediGene in a license agreement with the University of Chicago for targeting methodology to increase the efficiency of MediGene’s oncolytic herpes simplex virus therapy under phase I/II development

* Includes experience from a previous firm